YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Century Therapeutics press release [https://seekingalpha.com/pr/20616368-century-therapeutics-reports-second-quarter-2026-financial-results-and-business-updates] (IPSC [https://seekingalpha.com/symbol/IPSC]): Q2 GAAP EPS of -$0.17 misses…
Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 9, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) announced that its abstracts were accepted for oral presentations at two upcoming…
DelveInsight Business Research LLP The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune an…
The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $…
Advancing CNTY-813 as a potential functional cure in Type 1 DiabetesCNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical modelsAllo-Evasion™ 5.0 m…
Key Points HarbourVest initiated 1,722,210 shares of Generate Biomedicines last quarter; the estimated trade size was $21.03 million based on quarterly average prices. The quarter-end position value increased by $21.53 million, reflecting…
On May 15, 2026, HarbourVest Partners disclosed a new position in Generate Biomedicines(NASDAQ:GENB), acquiring 1,722,210 shares in the first quarter. The estimated transaction value is $21.03 million, based on quarterly average pricing. W…
Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the best performing small cap stocks so far in 2026. H.C. Wainwright lifted the price target on Century Therapeutics, Inc. (NASDAQ:IPSC) to $5 from $2 on April 21, maintaining a Buy rating…
New York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The iPSC-derived NK cells clinical trial analysis repo…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season ramps up and geopolitical tensions keep affecting the markets, below is a list of the top 10 healt…
Century Therapeutics Inc. (NASDAQ:IPSC) is one of the best fast growing penny stocks to buy according to analysts. On January 20, Piper Sandler increased its price target for Century Therapeutics to $4 from $2 with an Overweight rating, ci…
Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, and oral orexin 2 receptor agonist (formerly ALKS 2680), for the treatment of patients with narcolepsy type 1 (NT…
PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today…
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today…
* Century Therapeutics press release [https://seekingalpha.com/pr/20305898-century-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business] (IPSC [https://seekingalpha.com/symbol/IPSC]): Q3 GAAP EPS of -$0.40 misses…
Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026 CNTY-308 advancing through IND-enabling studies…
Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppression Compelling preclinical data demonstrate rapid reversal of diabetes and sustained…
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today…
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and canc…
* Century Therapeutics press release [https://seekingalpha.com/pr/20201838-century-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:IPSC [https://seekingalpha.com/symbol/IPSC]): Q2 GAAP EPS of -$0.3…
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now…
* Century Therapeutics (NASDAQ:IPSC [https://seekingalpha.com/symbol/IPSC]) may offer up to $200M in securities, including common stock, preferred stock, debt, warrants, units, and subscription rights. * Source: SEC filing [https://seeking…
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cance…
Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabli…
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and can…
PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and can…
Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 base…
- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - - Trial to evaluate and enhance clinical exp…
There are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change. And by pocket change, I’m talking almost literally. You’ve heard the expres…
PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that member…
- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the ongoing Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive B-cell lymphomas to be pr…
- Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovat…
PHILADELPHIA and MADISON, Wis., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun…
– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support, and a safety switch – –Preliminary clinical data from a case study feat…
PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today annou…
– Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended second quarter 2023 with cash, cash equivalents…